PNTG trades 12.2% below Wall Street's consensus target of $44.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PNTG achieves its forward estimates and maintains a stable P/E multiple of 28.4x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, The Pennant Group, Inc. (PNTG) has a Wall Street consensus price target of $44.50, based on estimates from 7 covering analysts. With the stock currently trading at $39.65, this represents a potential upside of +12.2%. The company has a market capitalization of $1.38B.
Analyst price targets range from a low of $40.00 to a high of $48.00, representing a 18% spread in expectations. The median target of $45.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PNTG trades at a trailing P/E of 47.2x and forward P/E of 28.4x. The forward PEG ratio of 2.82 reflects a premium valuation. Analysts expect EPS to grow +55.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $34.76, with bear and bull scenarios of $21.90 and $45.80 respectively. Model confidence stands at 52/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ADUSAddus HomeCare Corporation | $2.1B | $114.93 | $118.33 | +3.0% | Buy | 16.3x | 16 |
 ENSGThe Ensign Group, Inc. | $10.2B | $175.46 | $215.00 | +22.5% | Buy | 22.5x | 13 |
 NVSTEnvista Holdings Corp | $3.9B | $23.82 | $29.22 | +22.7% | Hold | 15.5x | 19 |
 NHCNational HealthCare Corporation | $3.5B | $225.01 | — | — | — | 28.2x | — |
 SGRYSurgery Partners, Inc. | $1.9B | $14.56 | $18.00 | +23.6% | Buy | 31.8x | 22 |
 OPCHOption Care Health, Inc. | $3.7B | $23.34 | $28.43 | +21.8% | Buy | 12.4x | 15 |
 HCSGHealthcare Services Group, Inc. | $1.5B | $21.25 | $26.50 | +24.7% | Hold | 17.7x | 15 |
 AVAHAveanna Healthcare Holdings Inc. | $2.8B | $12.79 | $14.38 | +12.4% | Buy | 22.0x | 12 |
 UNHUnitedHealth Group Incorporated | $337.2B | $371.29 | $473.89 | +27.6% | Buy | 18.7x | 52 |
 HUMHumana Inc. | $45.0B | $374.80 | $418.53 | +11.7% | Hold | 40.9x | 44 |
Quick answers to the most common questions about buying PNTG stock.
The Pennant Group, Inc. (PNTG) has a consensus 12-month price target of $44.5, implying 12.2% upside from $39.65. The 7 analysts covering PNTG see moderate appreciation potential.
PNTG has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $44.5 implies 12.2% upside from current levels.
PNTG trades at a forward P/E of 28.4087x, representing a moderate valuation. With analysts targeting $44.5 (12.2% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $48 for PNTG, while the most conservative target is $40. The consensus of $44.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $46 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
PNTG is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PNTG stock forecast based on 7 Wall Street analysts shows a consensus price target of $44.5, with estimates ranging from $40 (bear case) to $48 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $35, with bear/bull scenarios of $22/$46.
Our quantitative valuation model calculates PNTG's fair value at $35 (base case), with a bear case of $22 and bull case of $46. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 52/100.
PNTG trades at a forward P/E ratio of 28.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 47.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on PNTG, with a "Buy" consensus rating and $44.5 price target (12.2% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PNTG analyst price targets range from $40 to $48, a 18% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $44.5 consensus represents the middle ground. Our model's $22-$46 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.